Print    

Home Page / News and Events / Archived Releases / Press Release Details ...

April 7, 2008

BioTrove Combines Forces with OSI Pharmaceuticals to Enable Lead Discovery

Strategic Alliance Combines OSI's Lead Discovery Platform and BioTrove's RapidFire Screening Technology to Accelerate Client Lead Discovery

Woburn, MA, April 7, 2008 - BioTrove, Inc. today announced a new, non-exclusive marketing agreement with OSI Pharmaceuticals, Inc. to provide clients with a complete solution for lead compound discovery. Combining OSI Pharmaceuticals' Integrated Lead Discovery Platform with BioTrove's RapidFire mass spectrometry-based assay development, screening and analysis services, the agreement will enable customers to pursue challenging drug targets in a highly accurate, efficient and cost-effective manner.

"The collaboration addresses a critical, unmet need for companies in the biopharmaceutical industry, especially those without access to compound libraries or screening infrastructure," said Albert A. Luderer, Ph.D., President and CEO, BioTrove. "Our joint solution with OSI will enable increased research around novel targets for companies who may have crucial insights about disease progression, but do not specialize in large-scale high-throughput screening internally."

The companies' complete lead discovery service will provide access to OSI Pharmaceuticals' Integrated Lead Discovery Platform, enabling screening of large volumes of compounds against clients' target assays. BioTrove's mass spectrometry-based RapidFire platform, which enables label-free high-throughput screening using biological substrates, will be used to identify active compounds within chemical libraries.

"The synergistic combination of OSI's Lead Discovery Platform with BioTrove's RapidFire screening technology provides an innovative solution to early drug discovery, opening up a wide array of new targets for the biotechnology industry," said David Ghesquiere, Vice President, Corporate and Business Development, OSI Pharmaceuticals, Inc.
Financial terms were not disclosed

About BIOCIUS Life Sciences
BIOCIUS Life Sciences provides researchers faster answers to their lead discovery and in vitro ADME analyses through its RapidFire instrument and contract research services. RapidFire® enables the acceleration of drug discovery and pipeline decisions.  With 13 of the top 15 largest biopharmaceutical companies based on global sales as clients, and partnerships with prestigious research and public health centers around the world, BIOCIUS’s products and services ensure that an industry committed to accuracy and speed can meet business goals.

RapidFire® Mass Spectrometry (RF-MS) feeds samples directly to the mass spectrometer at six to eight seconds per sample, eliminating the bottleneck created by traditional mass spectrometry throughput. RF-MS is routinely used in many applications including the high-throughput screening of previously intractable drug targets and ADME assays.

BIOCIUS. Faster Answers.

RapidFire® technology is described in patent numbers 6,932,939, 6,812,030 7,100,460, 7,588,725,